Invivyd Announces Appointment of Communications Expert Kristie Kuhl As Chief Communications Officer

Invivyd, Inc. has announced the appointment of Kristie Kuhl as Chief Communications Officer. In this role, Kuhl will oversee the company’s communications strategy and patient advocacy initiatives as Invivyd continues its mission to develop monoclonal antibodies for the prevention and treatment of viral diseases.

Kuhl is a seasoned expert in healthcare and pharmaceutical communications, with a career distinguished by leadership in shaping high-impact narratives and advancing public understanding of complex medical innovations. She was recently recognized by PRWeek as part of its 2024 Health Influencer 30, highlighting her influence in the field. Before joining Invivyd, Kuhl served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm’s healthcare practice worldwide.

Expressing her enthusiasm for the new role, Kuhl said she is excited to join Invivyd during a critical time for both the company and the communities it serves. She noted that Invivyd’s science-driven approach and dedication to protecting people from serious viral illnesses call for bold, clear, and empathetic communication. Kuhl emphasized her eagerness to work closely with Invivyd’s leadership and teams to strengthen stakeholder trust, increase awareness of the company’s efforts, and support its growth.

Marc Elia, Chairman of the Invivyd Board of Directors, highlighted Kuhl’s extensive experience in building effective healthcare communications strategies and guiding teams through periods of change. He said her expertise will be vital as Invivyd works to establish strong scientific credibility and trust among patients, healthcare providers, payors, government agencies, and vulnerable populations. Elia added that he looks forward to collaborating with Kuhl to accelerate the company’s communications and advocacy efforts in line with its broader mission.

Kuhl’s appointment underscores Invivyd’s commitment to engaging patients and stakeholders while advancing its portfolio of monoclonal antibodies aimed at combating viral diseases. The company sees this step as essential to driving awareness, building trust, and supporting its long-term vision for public health.